# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Babe Didrikson Zaharias (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML038-SYN
- Date: 2026-03-30
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosalind Vasquez-Thornbury, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Diagnosis visit: biopsy and staging results, the tumor board plan, and the oncology and surgical consultations. **S**

## History of present illness

Ms. Didrikson Zaharias returns two weeks after her first visit. Colonoscopy three days after that visit found an ulcerated mass in the lower rectum, from 4 to 9 cm from the anal verge, and nothing else in the colon; the biopsies show adenocarcinoma, and the tumor has lost the mismatch repair proteins MSH2 and MSH6 and is microsatellite instability high. Rectal-protocol MRI shows a tumor whose lower edge is about 1 cm above the anorectal junction, growing just through the bowel wall, with two suspicious lymph nodes and a clear mesorectal fascia (cT3bN1). CT of the chest, abdomen and pelvis shows no spread. The tumor board met three days ago. She was seen today by Dr. Albright-Nakamura and by the colorectal surgeon, who explained that surgery for a tumor this low would most likely mean removing the rectum and anus with a permanent colostomy. She still passes some bright red blood most days, less than before, and feels tired on the back nine. Her first question was whether she would need a bag; her second was whether she could keep playing. **S**

| Element | Detail |
|---|---|
| Diagnosis | Low rectal adenocarcinoma, mismatch repair deficient (loss of MSH2 and MSH6), cT3bN1M0, stage IIIB |
| Procedures since the first visit | Colonoscopy with biopsy; rectal-protocol MRI of the pelvis; CT of the chest, abdomen and pelvis; tumor board |
| Tumor board | Dostarlimab every three weeks for six months, restaging about every three months, and watch-and-wait if the response is complete; chemoradiation and surgery in reserve |
| Symptoms | Less bleeding; still some urgency; tired late in a round |
| Her questions | Whether she will need a bag; whether she can keep competing; what the genetic test means for her brothers and sisters |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired late in a round; weight 62.6 kg, steady; no fever |
| Gastrointestinal | Positive | Bright red blood on most days, less than before; urgency; narrow stools |
| Genitourinary | Positive | Pain during sex and spotting afterwards; no urinary symptoms |
| Cardiovascular | Negative | No palpitations, fainting or leg swelling |
| Musculoskeletal | Negative | No back or pelvic pain |
| Psychiatric | Positive | Frightened by the word cancer and determined; PHQ-9 6, GAD-7 7; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/72 mmHg; pulse 80 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 62.6 kg; BMI 22.2 kg/m². All vital signs are synthetic.

Hemoglobin: 11.1 g/dL (low); White cell count: 6.5 10*3/uL; Platelets: 405 10*3/uL (high); Creatinine: 0.76 mg/dL; eGFR (CKD-EPI 2021): 101 mL/min/1.73 m²; Glucose: 90 mg/dL; ALT: 17 U/L; AST: 20 U/L; TSH: 1.9 mIU/L; Free T4: 1.2 ng/dL; PHQ-9: 6; GAD-7: 7. All results are synthetic.

## Change since baseline

- Hemoglobin: 11 g/dL (low) at baseline, 11.1 g/dL (low) at this visit **S**
- White cell count: 6.8 10*3/uL at baseline, 6.5 10*3/uL at this visit **S**
- Platelets: 412 10*3/uL (high) at baseline, 405 10*3/uL (high) at this visit **S**
- Creatinine: 0.78 mg/dL at baseline, 0.76 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 98 mL/min/1.73 m² at baseline, 101 mL/min/1.73 m² at this visit **S**
- Glucose: 88 mg/dL at baseline, 90 mg/dL at this visit **S**
- ALT: 18 U/L at baseline, 17 U/L at this visit **S**
- AST: 21 U/L at baseline, 20 U/L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Fit, tanned, composed; weight 62.6 kg; blood pressure 116/72, pulse 80 |
| Abdomen | Soft, non-tender; no liver enlargement or mass |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Rectal | With her agreement and a chaperone: firm, ulcerated, partly mobile mass on the posterior and left wall, lower edge about 4 to 5 cm from the anal verge; sphincter tone normal; blood on the glove |
| Psychiatric | Direct and focused; asks exact questions about her game and about a colostomy |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Low rectal adenocarcinoma, mismatch repair deficient, cT3bN1M0** (C20). Rectal cancer diagnosed two weeks after she first came, because the bleeding in a woman of 41 was examined and scoped at once rather than treated as hemorrhoids. It is locally advanced and low, so standard treatment would be chemoradiation and chemotherapy followed, in most cases, by an abdominoperineal resection and a permanent colostomy. Because the tumor is mismatch repair deficient, the tumor board and Dr. Albright-Nakamura recommend PD-1 blockade with dostarlimab for six months instead, which in the published trials has given a clinical complete response in nearly every patient with this kind of tumor and allowed the rectum to be kept, without radiation or surgery. She agreed, with the understanding that chemoradiation and surgery remain available if the response is not complete. **S**
   - Dostarlimab 500 mg every three weeks from next week, nine doses.
   - Hepatitis B, hepatitis C and HIV tests drawn today; urine pregnancy test negative today.
   - Germline multigene panel sent after counseling today.
   - Restaging MRI, sigmoidoscopy and rectal examination after four doses.
2. **Iron deficiency anemia from rectal blood loss** (D50.0). Hemoglobin 11.1 g/dL today (11.0 at the first visit, with ferritin 9 ng/mL); oral iron was started once the results had been reviewed; bleeding continues but is lessening. **S**
   - Ferrous sulfate 325 mg every other morning.
   - Blood count in four weeks; ferritin at three months.
3. **Rectal bleeding with a change in bowel habit and a rectal mass** (K62.5). Explained by the diagnosis made today; superseded. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Tissue diagnosis and mismatch repair testing | Before treatment; mismatch repair testing for every colorectal cancer | Up to date | Adenocarcinoma, moderately differentiated; loss of MSH2 and MSH6 on immunohistochemistry; microsatellite instability high |
| Imaging | Rectal-protocol MRI of the pelvis | At diagnosis, before any treatment | Up to date | cT3b, two suspicious mesorectal nodes (cN1), mesorectal fascia clear by 6 mm, no extramural venous invasion, lower edge about 1 cm above the anorectal junction |
| Imaging | CT of the chest, abdomen and pelvis | At diagnosis | Up to date | No metastases |
| Referral | Multidisciplinary tumor board | Before treatment for every rectal cancer | Up to date | Three days ago: dostarlimab, restaging, watch-and-wait if complete response |
| Referral | Colorectal surgery consultation | Before treatment of every rectal cancer | Completed today | Seen today: surgery now would most likely be abdominoperineal resection with a permanent colostomy; surgery kept in reserve for an incomplete response or regrowth |
| Referral | Wound-ostomy nursing: stoma site marking and teaching | Before any operation that may create a stoma | Not indicated | No operation planned; to be arranged at once if surgery becomes necessary |
| Laboratory | CEA | At diagnosis, at each restaging, then every three to six months for two years | Up to date | 5.8 ng/mL at the first visit; next with restaging |
| Examination | Digital rectal examination | At each oncology visit during treatment; every three to four months in watch-and-wait | Completed today | Lower edge about 4 to 5 cm from the anal verge; sphincter tone normal |
| Laboratory | Blood count | Before each dose of dostarlimab and at each visit; about four weeks after oral iron starts | Completed today | Hemoglobin 11.1 g/dL, white cells 6.5, platelets 405 |
| Laboratory | Kidney and liver function and glucose | At baseline and before each dose of PD-1 blockade | Completed today | Creatinine 0.76 mg/dL, eGFR 101; ALT 17 U/L, AST 20 U/L; glucose 90 mg/dL |
| Laboratory | TSH and free T4 | At baseline, then every six weeks on PD-1 blockade; six weeks after any levothyroxine change | Completed today | Baseline TSH 1.9 mIU/L, free T4 1.2 ng/dL |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before systemic cancer treatment | Ordered | Hepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody and HIV drawn today |
| Laboratory | Pregnancy test | Before treatment | Completed today | Urine pregnancy test negative |
| Medication safety | Contraception during PD-1 blockade | Throughout treatment and for four months after the last dose | Up to date | Levonorgestrel intrauterine device in place |
| Laboratory | Germline multigene panel | For every colorectal cancer diagnosed under 50 and every mismatch repair-deficient tumor | Ordered | Sent today after counseling |
| Referral | Genetic counseling | Before germline testing | Completed today | Pedigree as she knows it; she knows of no relative with a Lynch-associated cancer; consent for testing |
| Self-management | Teaching about immune-related adverse events | Before the first dose | Completed today | Written guide and 24-hour line: report diarrhea, blood in the stool, rash, cough, breathlessness, unusual tiredness, headache or thirst |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and at least yearly | Completed today | PHQ-9 6 (item 9 scored 0), GAD-7 7 |
| Self-management | Sexual health and body image | At diagnosis and through treatment | Completed today | Pain and spotting after sex explained by the tumor; told they should settle as it responds; a lubricant meanwhile |
| Self-management | Physical activity and sport | Each visit | Completed today | Encouraged to keep playing and training as she feels able; no restriction from dostarlimab |

## Goal progress

- Colonoscopy within one week, staging within two weeks, and a tumor board plan before treatment. Outcome by 2026-03-30: Colonoscopy in three days, MRI and CT within nine days, tumor board in eleven days, consultation at two weeks. **S**
- Germline genetic testing with counseling, and an explanation of the mismatch repair deficiency, within four weeks of diagnosis. In progress; target 2026-04-27. **S**
- Clinical complete response after six months of dostarlimab, with the rectum and sphincter preserved. In progress; target 2026-10-05. **S**
- Hemoglobin of 12 g/dL or more and ferritin above 30 ng/mL. In progress; target 2026-10-05. **S**
- Back to tournament golf during treatment. In progress; target 2026-06-29. **S**
- TSH within the reference range on thyroid replacement. In progress; target 2026-08-10. **S**
- PHQ-9 below 10 throughout treatment. In progress; target 2026-10-05. **S**

## Medication changes

- Started: Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morning **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026), National Comprehensive Cancer Network
- Scott AJ, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol 2024;42(28):3355-3375 (PMID 39116386) (2024), American Society of Clinical Oncology
- Cercek A, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022;386(25):2363-2376 (PMID 35660797) (2022), New England Journal of Medicine
- Cercek A, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med 2025;392(23):2297-2308 (PMID 40293177) (2025), New England Journal of Medicine
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology
- Tung N, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol 2024;42(21):2599-2615 (PMID 38759122) (2024), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026), Aether Forge

## Follow-up

- Dostarlimab cycle 1 next week. Primary care review at cycle 2. Call at once for heavy bleeding, fainting, diarrhea, rash, cough or breathlessness. **S**
- Next scheduled visit 2026-04-27: day 1 of cycle 2 of dostarlimab: early response, immune-related adverse event checks, germline and tumor genetic results, iron and anemia, and golf. **S**
